Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

No improvement in cognition seen with CERE-120 in Parkinson's disease patients

Feb. 8, 2008

TorreyPines reports results from phase I clinical trial of tezampanel for chronic pain

Feb. 7, 2008

Novel agents for psychological disorders disclosed in recent patent literature

Feb. 7, 2008

FDA extends PDUFA action date for GSK's Requip XL for Parkinson's disease

Feb. 7, 2008

Positive results reported for memantine once-daily formulation study

Feb. 7, 2008

ReNeuron schedules meeting with FDA to resolve IND hold for ReN-001

Feb. 7, 2008

Penwest announces results of a phase IIa clinical study of nalbuphine ER

Feb. 7, 2008

Alexza initiates AZ-007 phase I clinical trial

Feb. 6, 2008

Seaside awards USD 4.5 million collaborative research contract to Vanderbilt University

Feb. 6, 2008

Novel atypical antipsychotic drug profiled at Neurosearch

Feb. 6, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...